<DOC>
	<DOC>NCT00742105</DOC>
	<brief_summary>This study will confirm safety and tolerability and determine the MTD of BGT226 in Japanese patients with advanced solid tumor.</brief_summary>
	<brief_title>Phase I Study to Determine the Maximum Tolerate Dose (MTD) of BGT226 in Advanced Solid Tumors in Japan</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>World Health Organization (WHO) Performance Status of ≤ 2 Histologicallyconfirmed, advanced solid tumors Progressive, recurrent unresectable disease Age ≥ 20 Hematopoietic: No diabetes mellitus or history of gestational diabetes mellitus No acute or chronic renal disease No acute or chronic liver disease No acute or chronic pancreatitis No impaired cardiac function or clinically significant cardiac diseases such as ventricular arrhythmia, congestive heart failure, uncontrolled hypertension No acute myocardial infarction or unstable angina pectoris within the past 3 months Not pregnant or nursing and fertile patients must use barrier contraceptives Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>PI3K</keyword>
	<keyword>mTOR</keyword>
	<keyword>Advanced solid tumor</keyword>
	<keyword>Adult</keyword>
</DOC>